Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maralixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Recipient : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Abacus & Mirum Partner for the Commercialization of LIVMARLI in Nordic Markets
Details : Under the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.
Brand Name : Livmarli
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2024
Lead Product(s) : Maralixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Recipient : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
